secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001023024-26-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q1 rev $237.5M (+20.5%); raises FY 2026 guidance, authorizes $100M buyback
--------------------------------------------------------------------------------

- Q1 net revenue $237.5M (+20.5% YoY); GAAP diluted EPS $1.28; adj non-GAAP diluted EPS $2.05.
- Cortrophin Gel rev $75.1M (+42.1%); ILUVIEN rev $19.3M (+19.5%); Generics rev $105.4M (+6.8%).
- Raised FY 2026 guidance: rev $1,080M-$1,140M; adj EBITDA $285M-$300M; adj diluted EPS $9.19-$9.69.
- Board authorized $100M share repurchase program through May 2029; cash from operations $58.4M in Q1.
- Harmony Agreement contributed $15M upfront + $6.5M royalties; $10M milestone expected in Q2/Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/0001023024-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/ani-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001023024-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer